BBIO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
BridgeBio Pharma Inc (BBIO) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong revenue growth, positive Phase 3 trial results, and optimistic analyst ratings signal significant potential for long-term appreciation. Despite short-term earnings misses, the company's robust pipeline and expected profitability by 2028 make it a compelling investment opportunity.
The MACD histogram is negative and contracting (-0.709), RSI is neutral at 34.376, and moving averages are converging. The stock is trading near its support level (S1: 64.967), which could provide a potential entry point. However, the technical indicators do not show a strong bullish signal currently.
Positive Phase 3 results for Infigratinib in treating achondroplasia in children.
Revenue surged 2521.18% YoY in Q4
Analysts have raised price targets significantly, with some as high as $
Management expects to achieve over $600 million in profit by
Gross margin improved to 94.74%, up 46.72% YoY.
Q4 GAAP EPS missed expectations by $0.33, and net income dropped by 27.24% YoY.
Post-market price decline of -2.04%.
MACD and RSI indicators do not show strong bullish momentum.
In Q4 2025, revenue increased to $154.2 million, up 2521.18% YoY, driven by strong product sales. However, net income dropped to -$192.86 million (-27.24% YoY), and EPS fell to -$1 (-28.57% YoY). Gross margin improved significantly to 94.74%, indicating strong operational efficiency.
Analysts are overwhelmingly positive on BBIO, with multiple firms raising price targets recently. Targets range from $81 to $157, reflecting confidence in the company's growth potential, driven by its expanding product pipeline and strong sales momentum.
